1.Rangel-Frausto, MS, Pittet, D, Costigan, M, Hwang, T, Davis, CS, Wenzel, RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117–123.
2.Wenzel, RP. Anti-endotoxin monoclonal antibodies: a second look. N Engl J Med 1992;326:1151–1153.
3.Niederman, MS, Fein, AM. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia: a common clinical sequence. Clin Chest Med 1990;11:633–656.
4.Abraham, E, Wunderink, R, Silverman, H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934–941.
5.Zeni, F, Freeman, B, Natanson, C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095–1100.
6.Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia—United States, 1979-1987. MMWR 1990;39:31–34.
7.Reynolds, HN, Haupt, MT, Thill-Baharozian, MC, Charlson, RW. Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. JAMA 1988;260:3446–3450.
8.Pittet, D, Tarara, D, Wenzel, RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598–1601.
9.Edbrooke, DL, Hibbert, CL, Kingsley, JM, Smith, S, Bright, NM, Quinn, JM. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999;27:1760–1767.
10.Ridley, S, Biggam, M, Stone, P. A cost-benefit analysis of intensive therapy. Anaesthesia 1993;48:14–19.
11.Rentz, AM, Halpern, MT, Bowden, R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781–788.
12.Sands, KE, Bates, DW, Lanken, PN, et al. Epidemiology of sepsis syndrome in eight academic medical centers. JAMA 1997;278:234–240.
13.Bates, DW, Sands, K, Miller, E, et al. Predicting bacteremia in patients with sepsis syndrome. J Infect Dis 1997;176:1538–1551.
14.Bone, RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991;114:332–333.
15.Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal populations: development and validation. J Chronic Dis 1987;40:373–383.
16.SAS Institute, Inc. SAS Procedures Guide, Release 6.12 Edition. Cary, NC: SAS Institute, Inc.; 1996.
17.Pittet, D, Rangel-Frausto, S, Li, N, et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Medicine 1995;21:302–309.
18.Wey, SB, Mori, M, Pfaller, MA, Woolson, RF, Wenzel, RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642–2645.
19.Pittet, D, Thievent, B, Wenzel, RP, Li, N, Gurman, G, Suter, PM. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Medicine 1993;19:265–272.
20.Angus, DC, Linde-Zwirble, WT, Lidicker, J, Clermont, G, Cardilo, J, Pinsky, MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.